Literature DB >> 10397323

Production and purification of Clostridium botulinum type C and D neurotoxin.

F Gessler1, H Böhnel.   

Abstract

Neurotoxins of Clostridium botulinum are needed in basic neurologic research, but as therapeutic agent for certain neuromuscular disorders like strabism as well. A method for the production and purification of botulinum neurotoxins C and D is reported using a two-step hollow-fiber cross flow filtration and a newly developed chromatographic purification procedure. Hollow-fiber filtration proved to be a rapid and safe concentration and pre-purification step, which can easily be scaled up. The chromatographic purification included hydrophobic interaction, anion exchange and size exclusion chromatography runs. Botulinum neurotoxins C and D could be recovered with an overall yield of 12.6% and 10.6%, respectively. A specific toxicity of 1.86 x 10(7) minimal lethal dose mg(-1) (type C) and 5.26 x 10(7) minimal lethal dose mg(-1) (type D) was determined in the mouse bioassay.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10397323     DOI: 10.1111/j.1574-695X.1999.tb01306.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  3 in total

1.  Characterization of toxin complex produced by a unique strain of Clostridium botulinum serotype D 4947.

Authors:  Kimiko Hasegawa; Toshihiro Watanabe; Hiroaki Sato; Yoshimasa Sagane; Shingo Mutoh; Tomonori Suzuki; Akihito Yamano; Hirokazu Kouguchi; Kouichi Takeshi; Arihide Kamaguchi; Yukako Fujinaga; Keiji Oguma; Tohru Ohyama
Journal:  Protein J       Date:  2004-08       Impact factor: 2.371

2.  Sensitive detection of botulinum neurotoxin types C and D with an immunoaffinity chromatographic column test.

Authors:  Frank Gessler; Katrin Hampe; Helge Böhnel
Journal:  Appl Environ Microbiol       Date:  2005-12       Impact factor: 4.792

3.  Confirmation of botulism diagnosis in Australian bird samples by ELISA and RT rtPCR.

Authors:  Anne M Masters; Dieter G Palmer
Journal:  J Vet Diagn Invest       Date:  2021-05-06       Impact factor: 1.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.